Galapagos Presented New Atalanta-1 Cell Therapy Data In MCL
I'm PortAI, I can summarize articles.
Dec 8 (Reuters) - Galapagos NV (GLPG.AS) :REG-GALAPAGOS PRESENTED NEW ATALANTA-1 CELL THERAPY DATA IN MCL AT ASH 2025AMONG INFUSED PATIENTS OBJECTIVE RESPONSE RATE (ORR) WAS 100%, WITH COMPLETE RESPONSE RATE (CRR) OF 96%GLPG5101 SHOWS ENCOURAGING SAFETY PROFILE IN MCL STUDYGALAPAGOS REMAINS FOCUSED ON THE INTENTION TO WIND DOWN THE CELL THERAPY ACTIVITIESGLPG5101 DEMONSTRATED ROBUST IN VIVO CAR T-CELL EXPANSION AND LONG-TERM PERSISTENCE Source text: Further company coverage: (GLPG.AS)(Gdansk Newsroom)
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments